AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 21 - (NewsRx.com & NewsRx.net) -- Tumor cell vaccines containing nonviral vectors offer cancer prevention.
"We report that 100% mice survival after tumor challenge is achieved with cytokine-engineered cells employing nonviral lipoplexes and without using viral vectors. We describe this effect with cytokine-secreting tumor cell vaccines, based on cell clones or fresh transfected cells. Tumor cells were transfected with murine granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin (IL)-4 plasmids employing the cationic lipid DOTAP, were irradiated (150 Gy) and kept frozen until use," scientists in Spain report.
"The transfection efficacy was analyzed by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and flow cytometry. Vaccination induced potent antitumor rejection, resulting in 100% mice survival. Furthermore, the antitumor immunity was long lasting, since a twofold survival delay was observed in mice after tumor rechallenge (6 months later)," stated I. Moret-Tatay and colleagues, University of Valencia, Faculty of Medicine.
"While cell clones secreting GM-CSF were the most effective in wild-type tumor cell rejection, little or no effect was observed with clones secreting IL-4. We found similar antitumor efficacy employing fresh transfected ...
Source: HighBeam Research, Tumor cell vaccines containing nonviral vectors offer cancer...